Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 1 status confers therapeutic sensitivity to Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab in patients with Cervical Squamous Cell Carcinoma.
This statement is based on a regulatory approval from the Health Canada:
KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.